Digestive Colonisation by Highly Resistant Bacteria (CODBAHRE)
NCT ID: NCT04085380
Last Updated: 2020-10-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2396 participants
OBSERVATIONAL
2019-09-16
2020-07-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multi-Antibiotic Resistance Carriage in Gut Flora
NCT01591538
Emergence of Resistance in Intestinal Microflora During Carbapenem Treatments
NCT01703299
Rectal Carriage of Carbapenemase Producing-Enterobacteriaceae on Admission to a French University Teaching Hospital
NCT05798351
Prevalence of Digestive Carriage of Integrons
NCT01985217
Exposure to Antibiotics and Incidence of Bacteraemia Caused by Resistant Bacteria
NCT04065750
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All patients hospitalized more than 24 hours, on a given day are eligible for the protocol, except the patients unable to answer the questionnaire.
After collecting the non-opposition of the patient, patients will be screened by rectal swab and a questionnaire will be completed.
Each sample will be analyzed to detect eXDR carrying patients.
The carrying patients will be followed during 6 months to estimate the proportion of the population which developped a bacterial infection. This information will be collected by a retrospective telephone survey of carrying patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Give his no objection
Exclusion Criteria
* Unwilling to participate
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Direction Générale de l'Offre de Soins
OTHER_GOV
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Najiby Kassis-Chikhani, PhD
Role: PRINCIPAL_INVESTIGATOR
AP-HP, Hôpital Européen Georges Pompidou, Paris
Jean-Ralph Zahar, PhD
Role: PRINCIPAL_INVESTIGATOR
AP-HP, Hôpitaux Avicenne, Jean Verdier, et René Muret, Bobigny
Véronique Moulin
Role: PRINCIPAL_INVESTIGATOR
AP-HP, Hôpital Corentin Celton, et Vaugirard
Pierre Frange, PhD
Role: PRINCIPAL_INVESTIGATOR
AP-HP, Hôpital Necker enfants malades, Paris
Christine Lawrence, PhD
Role: PRINCIPAL_INVESTIGATOR
AP-HP, Hôpital Raymond Poincaré, Garches
Frédéric Barbut, PhD
Role: PRINCIPAL_INVESTIGATOR
AP-HP-Hôpital Saint Antoine, Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
HEGP
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APHP180561
Identifier Type: OTHER
Identifier Source: secondary_id
2019-A01226-51
Identifier Type: OTHER
Identifier Source: secondary_id
CODBAHRE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.